Wedbush Research Analysts Lift Earnings Estimates for ANRO

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities research analysts at Wedbush upped their FY2025 earnings per share estimates for Alto Neuroscience in a research report issued to clients and investors on Wednesday, November 12th. Wedbush analyst L. Chico now expects that the company will post earnings of ($2.20) per share for the year, up from their prior estimate of ($2.40). The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Wedbush also issued estimates for Alto Neuroscience’s Q4 2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.70) EPS.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday. Robert W. Baird raised their target price on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Chardan Capital started coverage on shares of Alto Neuroscience in a report on Monday, September 29th. They issued a “buy” rating and a $15.00 price target for the company. HC Wainwright upped their price target on shares of Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 24th. Finally, Jefferies Financial Group lifted their price objective on shares of Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $23.83.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $13.83 on Monday. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $15.18. The company has a current ratio of 15.42, a quick ratio of 15.42 and a debt-to-equity ratio of 0.20. The stock has a fifty day simple moving average of $7.91 and a two-hundred day simple moving average of $4.62. The stock has a market capitalization of $429.79 million, a price-to-earnings ratio of -6.04 and a beta of 2.81.

Institutional Trading of Alto Neuroscience

Institutional investors have recently modified their holdings of the company. Armistice Capital LLC grew its position in shares of Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after buying an additional 12,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in Alto Neuroscience by 1.9% in the third quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock valued at $4,444,000 after acquiring an additional 20,702 shares in the last quarter. Marshall Wace LLP boosted its stake in Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after acquiring an additional 84,417 shares in the last quarter. AWM Investment Company Inc. grew its holdings in Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after purchasing an additional 214,153 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Alto Neuroscience by 4.3% during the third quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock worth $1,269,000 after purchasing an additional 12,896 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.